SZodixStudyAcademic Library

Dashboard Shelves Open access My library Inbox Notes Write Learn Alerts

More

Ask your library Notifications Quick cite Review

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

The High Cost of Cancer Drugs and What We Can Do About It · Study

ArticleShelves

ArticleThe High Cost of Cancer Drugs and What We Can Do About It

Mustaqeem Ahmad Siddiqui2012

OA

Articlebronze2012

The High Cost of Cancer Drugs and What We Can Do About It

Mustaqeem Ahmad Siddiqui · S. Vincent Rajkumar

255 citations·0/0 files stored·Mayo Clinic Proceedings

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Economic and Financial Impacts of Cancer Pharmaceutical Economics and Policy Health Systems, Economic Evaluations, Quality of Life

Abstract

No abstract was published for this record.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 255 citations exist upstream.

References

1990EuroQol - a new facility for the measurement of health-related quality of life 1996The Role of Cost-effectiveness Analysis in Health and Medicine 1996The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine 2010Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs 2009Medical Bankruptcy in the United States, 2007: Results of a National Study 2006Calculating QALYs, comparing QALY and DALY calculations 1988A general health policy model: update and applications.2009Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs

Cited by

2016Advanced therapy medicinal products: current and future perspectives 2017Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund 2020The high cost of prescription drugs: causes and solutions 2018Health services costs for cancer care in Australia: Estimates from the 45 and Up Study 2022Barriers in access to oncology drugs — a global crisis

Related works

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

2001Decision Making in Health and Medicine: Integrating Evidence and Valuesarticle · 3 shared references 2002HALYs and QALYs and DALYs, Oh My: Similarities and Differences in Summary Measures of Population Healthreview · 3 shared references 1998Toward Consistency in Cost-Utility Analysesarticle · 3 shared references 2003Health Care Economic Analyses and Value-Based Medicinereview · 3 shared references 2005Validation of the EuroQol questionnaire in cardiac rehabilitationarticle · 3 shared references 1999Economic consequences of the progression of rheumatoid arthritis in Swedenarticle · 3 shared references

Details

Year2012

Typearticle

Published2012-10-01

VenueMayo Clinic Proceedings

ISSN-L0025-6196

Languageen

Citations255

Files0 public / 0

ShelfEconomic and Financial Impacts of Cancer

Identifiers

doi10.1016/j.mayocp.2012.07.007

openalex_workW1968004526

Links

Imported from OpenAlex (CC0) — nothing here is generated.

2015Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?

2014Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework

2021Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma